Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)

NCT00274742 is registered in ClinicalTrials.gov with Amgen Research (Munich) GmbH as lead sponsor.

NCT NCT00274742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00274742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL)
Lead sponsor
Amgen Research (Munich) GmbH
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2004
Completion date
April 30, 2012
Enrollment
76 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma, relapsed